Contract research organization NAMSA and preclinical and clinical research organization The Integra Group have formed a partnership that they hope will help medical device manufacturers get their products on the market faster.
The firms will jointly market services to medical device manufacturers across the United States and will coordinate projects for clients undergoing safety and efficacy evaluations for innovative medical technologies.
Company executives highlighted the benefits of having access to each other’s expertise. NAMSA claims strength in research and development, biocompatibility and clinical research, while The Integra Group claims proficiency in both non-clinical and clinical research. NAMSA recently opened new offices near Frankfurt, Germany, intended to provide clinical trial and regulatory support, so the benefits of having Integra by its side are immediately clear.
“Aligning the expertise of our people can facilitate medical device development through material selection, prototyping, non-clinical testing, and clinical research faster than other service providers,” said John Gorski, NAMSA president and CEO.
Chief medical officer of The Integra Group Roy Martin, M.D., said, “Combining our research models in non-clinical and clinical research with NAMSA's strength in biocompatibility and breadth of services makes us a stronger team together for the benefit of clients.”
The Integra Group, based in Brooklyn Park, Minn., is a relatively young company with about 50 employees.
Headquartered in Northwood, Ohio, NAMSA was founded in 1967. The company has been expanding its clinical research assets since 2010.